Artur Kadurin, Chief AI Officer and CEO of Insilico Taiwan, to present ‘AI in Drug Discovery Creates the Best Era of Precision Medicine’ at the 2018 Future Tech Forum
Credit: Insilico Medicine
Monday, December 10 – Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for Drug Discovery at 2018 Future Tech Forum, on December 14 in Taipei.
Artur Kadurin, Chief AI Officer and CEO of Insilico Taiwan, will deliver a keynote address titled “AI in Drug Discovery Creates the Best Era of Precision Medicine” during the Precision Medicine Forum. Mr. Kadurin will elaborate on current global healthcare trends and share insights into how Artificial Intelligence (AI) is emerging as a vital tool for drug development, creating the most accurate medical treatments of the future. Mr. Kadurin will account for Insilico’s international cooperation strategy, giving reasons for choosing Taiwan as its Asian R&D base.
Insilico Medicine launched its first Asian AI R&D base in Taiwan at the beginning of 2018. Insilico has partnered with Taiwan’s Development Center for Biotechnology (DCB), the Institute for Information Industry (III) and TUL Corporation to form the “AI Digital Health Talent Development Program,” to jointly develop AI expertise. Future courses on digital medicine, blockchain, and big data-related topics are being planned to strengthen Taiwan’s AI talent pool, solidifying Taiwan’s role as an AI R&D base for the rest of Asia.
Following Mr. Kadurin’s speech, experts from the fields of venture capital, academia, and clinical practice will engage in a panel discussion titled “Taiwan’s Chance in Precision Medicine is on Integration,” to further analyze international Precision Medicine trends and Taiwan’s role and contributions.
Participants will include Dr. James Chih-Hsin Yang, Director of the Department of Oncology, National Taiwan University Hospital, Dr. Hsing-Pang Hsieh, Associate Director of the Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, and Michel Chu, General Partner at Acorn Campus Taiwan.
Current, standardized, one-size-fits-all medical treatments of cancer and other diseases neglect patients’ individual differences, leading to highly inconsistent results. Such treatments can be extremely effective for some patients, while completely and frustratingly ineffective for the others. The new paradigm of “Precision Medicine” takes into account unique differences in individual patients, as well as the genetics of different kinds of cancers. Through deep understanding of each person’s genetic composition and the genetic variability of each tumor, Precision Medicine can create unique treatment methods, tailor-made for concrete patients and specific diseases.
Taiwan’s Precision Medicine industry is still developing. However, with rapid progress and deployment of new AI tools, combined with Taiwan’s deep pharmaceutical industry expertise and clinical trial knowledge, the 21st century promises to be a new era of Precision Medicine for Taiwan.
The Future Tech 2018 Exhibition, organized by Taiwan’s Ministry of Science and Technology (MOST), will include exhibits in four primary domains: Biotechnology and new drug development, Medical devices, Applied AI, electronics and optoelectronics, and Metal treatment chemicals and advanced materials. The Future Tech Forum will highlight three primary subjects: Precision medicine, Innovative AI applications, and Quantum computing.
For more information, please see the 2018 Future Tech website:
CEO of Insilico Taiwan Ltd.
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, MD with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research. Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson’s Disease, Alzheimer’s Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief.
Brief company video: https:/
News source: https://scienmag.com/